In Q3 2026, Baron Capital adjusted its portfolio by adding four new stock positions and exiting fourteen, resulting in a total of 33 holdings. Notably, the fund initiated a position in Biogen Inc., anticipating a transformative phase for the company. They also sold Madrigal Pharmaceuticals to reduce risk ahead of a competitor's clinical trial results. These moves reflect Baron Capital's active management strategy focused on growth and risk management.
Biogen Inc. (BIIB), one of the new positions added by Baron Capital in Q3 2026, trades at USD 250.67 on Pluang with a slight 1-day decrease of 0.01%. The stock's market cap stands at $37.04 billion, and it has a typical hold time of 111 days on the platform. These figures are current as of Oct 26, 2026 15:21 WIB.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Biogen is rated Hold as it approaches its Q3 2026 earnings report, expected on October 28. Analysts forecast revenues around $2.63 billion and normalized EPS of $1.98. The company faces challenges from patent expiries and competition in its MS and Al...
